# A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma

> **NCT02177110** · — · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 16 (actual)

## Conditions studied

- Advanced Melanoma
- Metastatic Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02177110
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2020-08
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177110, "A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02177110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*